Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) formation is the process by which relaxed circular DNA (rcDNA) is converted into cccDNA in the nucleus of infected hepatocytes. cccDNA serves as the transcriptional template for all HBV RNAs, including pregenomic RNA (pgRNA), and is essential for viral persistence and replication. The conversion of rcDNA into cccDNA involves removal of viral polymerase, terminal redundancy sequences, and RNA primers, completion of plus-strand DNA synthesis, and ligation. Host cell DNA repair machinery, including FEN1, TDP2, and POLK, are hijacked for this process. cccDNA forms a minichromosome structure that regulates gene expression. Targeting cccDNA formation is a key therapeutic strategy for achieving functional cure of chronic hepatitis B.
Inhibition of cccDNA formation or promotion of cccDNA degradation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B Virus cccDNA Formation.